This is a randomized, double-blind, placebo-controlled and multiple dose escalation phase Ib study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM383 in patients with Alzheimer's disease related mild cognitive impairment and mild Alzheimer's disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
48
CM383 injection
Matched placebo
The First Affiliated Hospital of University of Science and Technology of China
Hefei, China
RECRUITINGAdverse event
The occurrence of adverse events.
Time frame: Up to Week 26
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.